fda glp-1 warning letters september 2025 news sends letter after Chinese supplier breaks import restrictions What Patients Need to Know – September 8, 2025: FDA launches

Connect with the right partners and unlock new growth opportunities today:- United States: Recent Industry Developments March 2026: Eli Lilly and Company expanded manufacturing capacity for GLP-1 receptor agonists, supporting rising demand for type 2 diabetes and obesity management therapies

Because these drugs slow gastric emptying, choosing foods that are easier to digest can significantly reduce abdominal discomfort

Each meal and snack represents a vital opportunity to obtain essential nutrientsvitamins, minerals, protein, and fiber

The combination makes it physiologically easy to eat dangerously little, and for someone predisposed to disordered eating, this can reinforce harmful patterns rather than promote healthy weight management

For those with type 2 diabetes, these medications trigger insulin production to control blood sugar levels

Gastrointestinal symptoms during dose changes Nausea, constipation, and other GI symptoms are the most common side effects of GLP-1 therapy, and they tend to re-emerge whenever dosing changes occur